RT Journal Article
SR Electronic
T1 Healthcare visits of the population 50+ in Europe from 2004 to 2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.10.24310226
DO 10.1101/2024.07.10.24310226
A1 Nguyen, Van Kinh
A1 Reuter, Anna
A1 El Aziz, Mirna Abd
A1 Bärnighausen, Till
YR 2024
UL http://medrxiv.org/content/early/2024/07/10/2024.07.10.24310226.abstract
AB Background Guaranteeing access to healthcare among the older population is essential to the planning and preparation of health services. We describe the health care visits among the population 50+ across 27+ European countries, the spatio-temporal trends and determinants, and the changes during and after the COVID-19 pandemic.Methods We used individual panel data from 27 European countries across 10 waves of the Survey of Health, Ageing and Retirement in Europe. We analysed the number of healthcare visits (NHV) over time and their correlation with age and chronic conditions using a Bayesian spatio-temporal model.Results The nominal rate of healthcare visits varied among countries from two to five visits per year and increased over time, with a slight convergence across countries. The NHV were higher for women and increased approximately linearly with age. Individuals with chronic conditions had a 20%–60% higher NHV, with the largest difference for individuals with cancer. The COVID-19 epidemic severely affected the NHV, with an estimated reduction from 65% to 95%. During COVID-19, older individuals and those with chronic conditions had a more than proportional reduction in the NHV. After COVID-19, the pattern of NHV mostly returned to pre-pandemic levels, with an over-shooting for people with cancer and a lag for people with cardiovascular diseases.Conclusion The quick recovery in the NHV for most European countries indicate that access to care stabilised again. Yet, gap in care during COVID-19 was more than proportionate for vulnerable groups, such that these groups require timely action to prevent long-term consequences of missed care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch in this article is a part of the European Union's H2020 SHARE COVID-19 project (Grant Agreement No. 101015924).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SHARE study was approved by the Ethics Committee at the University of Mannheim (waves 1-4) and by the Ethics Council of the Max-Planck-Society (waves 5-8). Additionally, country-specific ethics committees or institutional review boards pproved implementations of SHARE in the participating countries. All study participants provided informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAccess to the data can be granted by the SHARE project (http://share-eric.eu/). https://share-eric.eu/data/